BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On April 12, 2017, BioCryst Pharmaceuticals, Inc. (BioCryst)
announced plans to explore a new oral liquid formulation of
BCX7353 for the treatment of acute attacks in patients with
hereditary angioedema (HAE).
On April 12, 2017, the Company issued a news release announcing
the events described in this Item 7.01. A copy of the news
release is filed as Exhibit 99.1 hereto and is incorporated
herein by reference.
The information furnished in this Item 7.01 is not deemed filed
for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, is not subject to the liabilities of that
section and is not deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such a filing.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking
statements, including statements regarding future results,
performance or achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause
BioCrysts actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with
respect to future events and are based on assumptions and are
subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking
statements. Some of the factors that could affect the
forward-looking statements contained herein include: developing
any HAE drug candidate may take longer or may be more expensive
than planned; ongoing and future preclinical and clinical
development of HAE second generation drug candidates (including
APeX-1 and ZENITH-1) may not have positive results; that BioCryst
may not be able to enroll the required number of subjects in
planned clinical trials of product candidates; that the Company
may not advance human clinical trials with product candidates as
expected; that the FDA may require additional studies beyond the
studies planned for product candidates, or may not provide
regulatory clearances which may result in delay of planned
clinical trials, or may impose a clinical hold with respect to
such product candidate, or withhold market approval for product
candidates; that BioCryst may not receive additional government
funding to further support the development of galidesivir; that
galidesivir development may not be successful; that BARDA and/or
NIAID may further condition, reduce or eliminate future funding;
that revenue from peramivir injection is unpredictable and may
never result in significant revenue for the Company; that the
Company may not be able to continue development of ongoing and
future development programs; that such development programs may
never result in future products; that actual financial results
may not be consistent with expectations, including that 2017
operating expenses and cash usage may not be within management’s
expected ranges. Please refer to the documents BioCryst files
periodically with the Securities and Exchange Commission,
specifically BioCrysts most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K,
all of which identify important factors that could cause the
actual results to differ materially from those contained in
BioCrysts projections and forward-looking statements.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
99.1 |
Press Release dated April 12, 2017 entitled BioCryst |
About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Recent Trading Information
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed its last trading session up +0.05 at 7.22 with 1,240,712 shares trading hands.